232,984 IDEXX Laboratories, Inc. $IDXX Shares Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its IDEXX Laboratories stake by 99.6% in the third quarter, selling 232,984 shares and retaining 948 shares worth approximately $495,000. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly EPS of $4.27, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company maintained fiscal 2026 EPS guidance of $14.69–$14.94.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $744.09, despite some target reductions and neutral ratings. IDXX recently traded at $560.36, with a market capitalization of about $44.15 billion.

Curated Wealth Partners LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 948 shares of the company's stock after selling 232,984 shares during the period. Curated Wealth Partners LLC's holdings in IDEXX Laboratories were worth $495,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of IDXX. Aurora Investment Managers LLC. acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at $2,442,000. National Pension Service boosted its position in shares of IDEXX Laboratories by 5.6% during the 2nd quarter. National Pension Service now owns 129,305 shares of the company's stock valued at $68,071,000 after acquiring an additional 6,885 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of IDEXX Laboratories by 60.9% during the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company's stock valued at $8,552,000 after buying an additional 5,761 shares during the period. Arizona State Retirement System lifted its stake in shares of IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company's stock valued at $11,988,000 after purchasing an additional 1,074 shares during the last quarter. Finally, SVB Wealth LLC increased its position in shares of IDEXX Laboratories by 17.4% during the first quarter. SVB Wealth LLC now owns 7,335 shares of the company's stock valued at $4,121,000 after acquiring an additional 1,089 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.79% of the company's stock.

IDEXX Laboratories Stock Up 2.4%

IDXX stock opened at $560.36 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm has a market capitalization of $44.15 billion, a PE ratio of 39.41, a P/E/G ratio of 2.92 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The company's 50 day simple moving average is $534.22 and its 200-day simple moving average is $551.84.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter last year, the business posted $3.50 EPS. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.80 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on IDXX. UBS Group increased their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Barclays lowered their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. KeyCorp assumed coverage on IDEXX Laboratories in a research report on Monday. They issued a "sector weight" rating on the stock. Finally, Citigroup lifted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Seven analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $744.09.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.